EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli

Tae Yeul Kim iD, Jin Yang Baek, Eunsang Suh, Jun-Ki Lee, Hui-Jin Yu, Jae-Hoon Ko iD, Hee Jae Huh iD, Nam Yong Lee iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.00166-25 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Tae Yeul Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Colistin, Anti-Bacterial Agents, Gram-Negative Bacteria, Carbapenems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We assessed the performance of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations and colistin in carbapenem-non-susceptible gram-negative isolates. A total of 425 clinical isolates, including Enterobacterales ( n = 242), Pseudomonas aeruginosa ( n = 97), and Acinetobacter baumannii ( n = 86), were tested using VITEK 2, with broth microdilution as the reference standard. Minimum inhibitory concentrations were interpreted according to Clinical and Laboratory Standards Institute breakpoints. The essential agreement (EA), categorical agreement (CA), very major error rate, and major error rate for VITEK 2 were 90.3%, 97.6%, 1.8%, and 2.5% for ceftazidime/avibactam; 81.5%, 89.0%, 7.0%, and 4.7% for ceftolozane/tazobactam; 96.5%, 90.9%, 3.4%, and 1.2% for imipenem/relebactam; and 94.6%, 93.0%, 15.8%, and 3.2% for meropenem/vaborbactam. For colistin, VITEK 2 demonstrated an EA of 89.2% and a CA of 85.4%. Our findings suggest that VITEK 2 has suboptimal performance for novel BL/BLI combinations in carbapenem-non-susceptible gram-negative isolates. Furthermore, despite changes to the colistin formulation used in the VITEK 2 card, it remains an unreliable method for detecting colistin resistance. IMPORTANCE Rapid and accurate antimicrobial susceptibility testing (AST) is essential for managing infections caused by multidrug-resistant gram-negative bacilli. This study evaluated the performance of the VITEK 2 AST-N439 card for susceptibility testing of novel BL/BLI combinations and colistin in carbapenem-non-susceptible gram-negative isolates. Our findings revealed significant limitations, including suboptimal performance for novel BL/BLI combinations and unreliable detection of colistin resistance, even with the updated formulation. These results underscore the need for cautious interpretation of VITEK 2 results and highlight the importance of optimizing its performance to enhance antibiotic decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColistinAnti-Bacterial AgentsGram-Negative BacteriaCarbapenemsbeta-Lactamase Inhibitorsbeta-LactamsMicrobial Sensitivity TestsHumansGram-Negative Bacterial InfectionsAcinetobacter baumanniiAzabicyclo CompoundsCeftazidimePseudomonas aeruginosaDrug CombinationsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

VITEK 2colistingram-negative bacillinovel BL/BLI combinationssusceptibility testing

Substanzen

ColistinAnti-Bacterial AgentsCarbapenemsbeta-Lactamase InhibitorsAzabicyclo CompoundsCeftazidimebeta-LactamsDrug Combinations

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea.
  • Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Laboratory Medicine, Seoul Medical Center, Seoul, Republic of Korea.
  • Department of Medical Device Management and Research, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea.

ORCID-Profile: Tae Yeul Kim, Jae-Hoon Ko, Hee Jae Huh, Nam Yong Lee

Förderung

  • Korea Health Industry Development Institute

Zitieren

APA

Kim, T. Y., Baek, J. Y., Suh, E., Lee, J. K., Yu, H. J., Ko, J. H., Huh, H. J., & Lee, N. Y. (2025). Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00166-25

Vancouver

Kim TY, Baek JY, Suh E, Lee JK, Yu HJ, Ko JH, et al. Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli. Microbiology Spectrum. 2025. doi:10.1128/spectrum.00166-25

BibTeX
@article{Kim2025,
  author = {Kim, Tae Yeul and Baek, Jin Yang and Suh, Eunsang and Lee, Jun-Ki and Yu, Hui-Jin and Ko, Jae-Hoon and Huh, Hee Jae and Lee, Nam Yong},
  title = {Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.00166-25}
}
Kostenlos starten →